An Open Study of the Safety and Pharmacokinetics of a Medicinal Product for Emergency Prevention of Ebola (03-AT-2017)
An Open, Dose Escalation Safety and Pharmacokinetics Study of the Medicine for Ebola Fever Emergency Prevention Based on Monoclonal Recombinant Antibodies With a Single Application in 3 Groups of Healthy Volunteers
Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
A PHASE1 clinical study on Healthy, this trial is completed. The trial is conducted by Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation and has accumulated 10 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Feb 2019 — Dec 2019 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Nov 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Mar 2018 — Apr 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Research Institute of Influenza, Sankt-Peterburg, Russian Federation
For direct contact, visit the study record on ClinicalTrials.gov .